Podcast appearances and mentions of David R Jones

This Day in Legal History: McKinley Assassin Stands TrialOn September 23, 1901, the trial of Leon Czolgosz began for the assassination of President William McKinley. Czolgosz, an anarchist, had shot McKinley on September 6 at the Pan-American Exposition in Buffalo, New York. Despite efforts to save him, McKinley died eight days later from gangrene caused by the bullet wounds. The trial was swift, lasting only eight hours over two days, as Czolgosz had already confessed to the crime. His defense team, appointed by the court, argued that Czolgosz was insane, but he refused to cooperate with his lawyers or plead insanity.The prosecution presented overwhelming evidence, including eyewitness testimonies and the fact that Czolgosz shot McKinley at point-blank range in a public setting. The jury deliberated for less than 30 minutes before finding him guilty of first-degree murder. Czolgosz was sentenced to death and was executed by electric chair on October 29, 1901. His trial and execution sparked discussions about the influence of anarchism in the U.S. and led to increased efforts to suppress political radicalism in the early 20th century.From a presidential assassin from history to a would-be modern day presidential assassin, Ryan W. Routh, a 58-year-old suspect accused of attempting to assassinate former U.S. President Donald Trump, is set to appear in court on Monday. Routh allegedly hid near Trump's Florida golf course on September 15, pointing a rifle through the tree line while Trump played golf. Although he did not fire a shot and lacked a direct line of sight to Trump, who was several hundred yards away, Routh was charged with two gun-related crimes: possession of a firearm as a convicted felon and possession of a firearm with an obliterated serial number. Additional charges may follow.A Secret Service agent spotted the weapon and fired in Routh's direction, causing him to flee. He was later arrested on a nearby highway. Prosecutors are expected to argue for his detention, citing public safety concerns. The FBI is investigating the incident as an apparent assassination attempt ahead of the upcoming November presidential election. Authorities have not yet disclosed a motive, though Routh, a convicted felon with a history of supporting Ukraine, previously made statements in a self-published book suggesting that Trump could be a target for assassination. Cellphone data shows Routh may have been in the area for 12 hours before being apprehended.Trump attempted assassination suspect Ryan Routh to appear in court | ReutersAn appeals court panel recently reviewed procedural issues in Stephen Thaler's attempt to copyright an AI-generated image, raising concerns that the court may avoid larger questions about AI and copyright law. Thaler argued that his AI, the "Creativity Machine," autonomously created the work in question, but the U.S. Copyright Office rejected his application, and a lower court dismissed his case. The court found that Thaler had waived the argument that he was the author by continuing to claim the machine was the creator.During the appeal, the judges suggested that Thaler's argument may be barred since his appellate brief did not challenge the lower court's finding that he had waived his authorship claim. Legal experts fear this focus on procedural flaws could prevent the court from addressing significant issues about the role of human creativity in AI-generated works.If the court rules that AI-created works cannot be copyrighted, it could have far-reaching effects, leaving AI-generated content like images and text unprotected and placing them in the public domain. The court's decision may not close the door on AI-assisted works, but it raises questions about where the line is drawn between human and machine-generated creativity. The case highlights ongoing uncertainties about how copyright law will adapt to AI's growing role in creative industries. The key legal issue here is the court's focus on procedural waiver, which may limit the scope of the ruling and leave broader questions about AI and copyright unresolved.AI Art Appeal's Procedural Flaws Put Broader Ruling in DoubtThe U.S. Federal Trade Commission (FTC) has sued the three largest pharmacy benefit managers (PBMs)—UnitedHealth's Optum, CVS Health's Caremark, and Cigna's Express Scripts—accusing them of inflating insulin prices to gain larger rebates from pharmaceutical companies. The FTC claims that these PBMs steered patients towards higher-priced insulin by excluding cheaper alternatives from coverage, harming those with coinsurance or deductibles who couldn't benefit from the rebate. Together, these three companies control 80% of U.S. prescriptions.The PBMs denied the allegations, arguing that their practices have lowered insulin costs for businesses and patients. The case represents a significant step in the Biden administration's push to lower drug prices, particularly insulin, which has seen soaring costs over the past decade. FTC Deputy Director Rahul Rao labeled the PBMs as "medication gatekeepers," accusing them of profiting at the expense of diabetic patients.The lawsuit did not target insulin manufacturers like Eli Lilly, Sanofi, and Novo Nordisk but criticized their role in the system. The drugmakers supported reforms to lower patient costs and highlighted their programs to cap insulin prices at $35. The FTC's suit aims to address broader concerns about the U.S. healthcare system's structure and the rising cost of life-saving medications like insulin.US FTC sues drug 'gatekeepers' over high insulin pricesFTC Sues CVS, Cigna, UnitedHealth Over Rising Insulin Costs (1)Jackson Walker LLP is facing disciplinary action after a federal judge found the Texas law firm breached its ethical duties by failing to disclose a secret relationship between one of its attorneys, Elizabeth Freeman, and former Houston bankruptcy judge David R. Jones. Judge Marvin Isgur issued a scathing letter on Friday, criticizing the firm for concealing the affair, which he said violated professional responsibilities and "defiled the very temple of justice." Isgur recused himself from cases involving the firm following this recommendation.The relationship came to light after Freeman, a former partner at Jackson Walker, continued to see Jones despite telling the firm in 2021 that the relationship had ended. Isgur accused the firm of knowingly withholding this information from clients and the court, calling it an "inconceivable" ethical breach. The U.S. Trustee is now attempting to recover up to $18 million in fees earned by Jackson Walker in cases overseen by Jones while he was dating Freeman.The disciplinary case has been referred to Judge Lee H. Rosenthal, and Jackson Walker faces potential penalties, including disbarment or suspension. The firm denies violating ethical rules and claims Freeman misled them. However, Isgur emphasized that the firm's decision to protect itself at the expense of its clients and professional obligations was "intolerable." A public hearing is expected to follow, giving Jackson Walker a chance to respond to the charges.Jackson Walker ‘Defiled the Very Temple of Justice,' Judge Says This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Almost a year ago, the public first learned that David R. Jones, a now former federal judge, was in a secret, live-in romantic relationship with a partner at a bankruptcy firm that had lots of business in Jones' Houston court. Since then, Jones has stepped down from the bench, but the dust has definitely not settled. The federal bankruptcy monitor is trying to claw back millions in attorneys' fees that the firm, Jackson Walker, collected in cases overseen by Jones. And Jones himself is in more hot water after he sat down for an off-the-record interview with Jackson Walker—without approval from the judge investigating the whole matter. To untangle this messy situation, Bloomberg Law reporter James Nani joins our podcast, On The Merits, and talks about why Jones says he's done nothing wrong and whether Jackson Walker's reputation can come out of this intact. Do you have feedback on this episode of On The Merits? Give us a call and leave a voicemail at 703-341-3690.

This Day in Legal History: Lincoln Signs the Second Confiscation ActOn July 17, 1862, President Abraham Lincoln signed the Second Confiscation Act into law, marking a significant legal development during the Civil War. This act allowed for the seizure of property owned by individuals engaged in rebellion against the Union. Unlike previous measures, it did not require due process or provide an opportunity for the accused to defend themselves. The act targeted Confederate supporters, intending to weaken the rebellion by stripping resources from those aiding the Confederate cause. The legislation also declared that enslaved people who escaped from rebel owners or were captured by Union forces would be considered free. This move was a precursor to the Emancipation Proclamation and signaled a shift in Union policy towards a more aggressive stance against slavery. The Second Confiscation Act was controversial, as it raised significant legal and constitutional questions regarding property rights and due process. Critics argued it overstepped executive powers and violated the Fifth Amendment.Despite these concerns, the act was a critical step in undermining the Confederate war effort and advancing the Union's moral and strategic objectives. It reflected the growing commitment of the Lincoln administration to not only preserve the Union but also to end slavery. The Second Confiscation Act thus played a pivotal role in the broader legal and political landscape of the Civil War.President Joe Biden is preparing to introduce proposals for significant Supreme Court reforms, including imposing term limits on justices, who currently serve for life. This marks a notable shift for Biden, who has previously resisted such reforms despite pressure from within his party. The proposals also include an enforceable ethics code for justices and a constitutional amendment to overturn a recent Supreme Court decision granting broad immunity to presidents for official actions.However, these changes are expected to face considerable challenges in becoming law, especially with Congress unlikely to address major legislation before the upcoming election. Biden's proposals come amidst a tight race against former President Donald Trump, who leads in public opinion polls. Congressional Republicans are expected to oppose the reforms, viewing the current conservative Supreme Court as a significant political achievement.The White House has yet to consult with key lawmakers about the plans, and Press Secretary Karine Jean-Pierre has declined to comment. Biden hinted at these proposals in a recent call with the Congressional Progressive Caucus, aiming to garner support after a poor performance in a presidential debate. The Democratic push for Supreme Court reform has grown following several controversial rulings, including the overturning of Roe v. Wade and the rejection of Biden's student loan cancellation plan. Justice Clarence Thomas has also faced scrutiny for not disclosing expensive gifts from conservative donors. The court's decision granting presidential immunity for official acts has further complicated efforts to prosecute Trump. Biden criticized this decision, arguing it contradicts the founders' intentions. In response, Trump accused Democrats of undermining the Supreme Court and interfering in the presidential election. Biden to Propose Supreme Court Reforms, Including Term LimitsBiden seriously considering proposals on Supreme Court term limits, ethics code, AP sources sayFederal prosecutors in Alaska have identified 23 criminal cases with potential conflicts of interest involving former U.S. District Judge Joshua Kindred, who resigned following sexual misconduct allegations. The 9th Circuit Judicial Council reprimanded Kindred for creating a hostile work environment and engaging in an inappropriate relationship with a law clerk. Although the clerk did not work on cases before Kindred, potential conflicts existed in other cases.Bryan Wilson, head of the U.S. Attorney's Office's criminal division, detailed the conflicts in an email to Alaska's federal public defender. These conflicts included interactions between Kindred and several attorneys, such as a senior prosecutor who sent him nude photos and another attorney who exchanged flirtatious texts. These undisclosed conflicts could lead defense lawyers to challenge convictions or sentences from cases Kindred oversaw.The U.S. Attorney's Office had taken steps to mitigate conflicts since late 2022 by notifying the district's chief judge and reassigning cases from Kindred. However, Federal Public Defender Jamie McGrady criticized the office for not disclosing the conflicts sooner and noted that the recusal of Kindred did not eliminate prejudice against defendants. Her office plans to investigate all cases involving attorneys who interacted with Kindred to ensure justice.Former Alaska judge had potential conflicts in 23 cases, prosecutors say | ReutersA federal appeals court ruled that Minnesota's law requiring individuals to be at least 21 to obtain a permit to carry a handgun in public for self-defense is unconstitutional. The 8th U.S. Circuit Court of Appeals found the law violated the Second Amendment rights of 18- to 20-year-olds. U.S. Circuit Judge Duane Benton, writing for the panel, emphasized that the Second Amendment does not specify an age limit.The court upheld a previous ruling in favor of the Second Amendment Foundation, the Firearms Policy Coalition, and the Minnesota Gun Owners Caucus, which had challenged the law. The decision referenced the 2022 Supreme Court ruling in New York State Rifle & Pistol Association v. Bruen, which set a new standard for evaluating firearm regulations, stating they must align with the nation's historical tradition of firearm regulation.Judge Benton noted that Minnesota failed to show that 18- to 20-year-olds posed specific risks that justified the age restriction. Despite this, the Supreme Court had recently upheld a federal ban on gun possession for individuals under domestic violence restraining orders, indicating that certain modern firearm restrictions could be valid without historical precedent.Minnesota Attorney General Keith Ellison expressed disappointment with the ruling, arguing it complicates efforts to reduce shootings and enhance public safety. This decision is part of a broader trend of gun rights groups challenging age-based firearm restrictions in various states.Minnesota cannot bar adults under 21 from carrying guns, court rules | ReutersTesla has replaced its long-time law firm, Cravath, Swaine & Moore, with Wilmer Cutler Pickering Hale and Dorr in a California class action antitrust case. This change, noted in court records, comes as Tesla faces allegations of monopolizing the market for vehicle parts and services, which has purportedly led to consumers paying higher prices. The reason for the switch was not disclosed, and neither Tesla nor the involved law firms commented.The class action case saw a significant development in June when a judge refused to dismiss the claims against Tesla. Shortly thereafter, Wilmer attorneys made their debut appearance for Tesla, continuing to deny the plaintiffs' allegations. Tesla and Musk have a history of legal representation by both Cravath and Wilmer in various high-profile cases.Musk is also represented by Cravath in a Delaware lawsuit challenging his $56 billion pay package, a case that faced a setback in January when a judge invalidated the compensation. Despite a shareholder vote in favor of Musk's pay in June, the Delaware litigation continues, with Quinn Emanuel Urquhart & Sullivan recently joining the defense team.Wilmer is defending Tesla in another antitrust lawsuit in New Orleans, where it seeks to overturn a ban on direct-to-consumer car sales. The new Wilmer team for the California case includes partners David Gringer and Ari Holtzblatt, while the departing Cravath team comprised David Marriott and Vanessa Lavely.Tesla swaps law firms in antitrust case as Cravath exits | ReutersThe questioning of former bankruptcy judge David R. Jones, who resigned after revealing a secret relationship with a partner at Texas law firm Jackson Walker, has been postponed. The US Trustee's office is investigating to recover over $13 million in fees Jones approved for Jackson Walker without disclosing the relationship. Chief Judge Eduardo V. Rodriguez of the Houston bankruptcy court is deliberating on whether the questions about Jones' recusal decisions and his relationship with the attorney violate judiciary policy.Jones, who resigned last year, had a relationship with Elizabeth Freeman, who left Jackson Walker in late 2022. The deposition, originally set for July 18, is on hold until Judge Rodriguez determines the appropriateness of the questions. Jones' attorney, Benjamin I. Finestone, argues that questions about Jones' conduct are a distraction and that the focus should be on what Jackson Walker knew about the relationship.Jackson Walker's attorney, Jason Lee Boland, asserts that understanding the timeline of Jones and Freeman's relationship is crucial for defending against the US Trustee's efforts to reclaim the fees. Judge Rodriguez emphasized the complexity of addressing questions about judges' recusal decisions, stating that such decisions should not be publicly questioned. US Trustee attorney Laura Steele argued that Jones' public statements about his recusals allow for relevant inquiries.The case, known as Professional Fee Matters Concerning the Jackson Walker Law Firm, continues as the court navigates the boundaries of questioning a judge's conduct and recusal decisions.Bankruptcy Court Likely to Pare Back Probe into Ex-Judge Romance This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Last week's highlights include Fisker's chapter 11 filing, Hertz's $1 billion debt raise, a ruling in the Invesco/Robertshaw dispute over “required lender” status and David Boies joining former bankruptcy judge David R. Jones' defense team. And, as always, we provide a preview of what's on tap for this week. We're taking a brief recess from our weekly interview segment this week but will be back next week with more premium content. For more information on our latest events and webinars, visit reorg.com/resources/events-and-webinars/ Sign up for our weekly newsletter, Reorg on the Record: reorg.com/resources/reorg-on-the-record We're looking for feedback to improve the podcast experience! Please share your thoughts by taking the survey:https://www.research.net/r/Reorg_podcast_survey

This Day in Legal History: Act of Toleration EnactedOn May 24, 1689, the Parliament of England enacted the Act of Toleration, a pivotal law that granted religious freedom to English Protestants. This legislation marked a significant shift in England's religious landscape, as it allowed non-Anglican Protestants, such as Baptists and Congregationalists, to practice their faith without fear of persecution. However, this tolerance came with limitations: it excluded Roman Catholics and non-Trinitarian Protestants, leaving them outside the protection of the Act.The Act of Toleration emerged in the context of the Glorious Revolution, which saw William of Orange and his wife Mary ascend to the English throne. Their reign, beginning in 1688, was characterized by a move towards greater religious and political stability. The Act was a response to the religious strife that had plagued England for decades, providing a framework for more inclusive, albeit limited, religious coexistence.Despite its exclusions, the Act of Toleration laid the groundwork for future expansions of religious freedom. It required dissenting Protestants to pledge allegiance to the Crown and reject the authority of the Pope, thus maintaining a degree of control over the newly tolerated groups. This compromise allowed for religious diversity while ensuring loyalty to the monarchy.The Act's passage was a milestone in the evolution of religious liberty in England, reflecting the changing attitudes towards religious pluralism. While it did not end all religious discrimination, it represented a step towards a more tolerant society. Over time, the principles enshrined in the Act influenced broader movements for religious freedom and civil rights, both in England and beyond.The significance of the Act of Toleration lies not only in its immediate effects but also in its lasting impact on the development of religious tolerance as a fundamental value in democratic societies.A Democratic operative, Steve Kramer, faces state criminal charges and a federal fine for using AI to fake President Joe Biden's voice in robocalls aimed at discouraging Democratic voters in the New Hampshire primary. Kramer, working for Biden's primary challenger Dean Phillips, was charged with 13 felony counts of voter suppression and 13 misdemeanors for impersonating a candidate. The FCC proposed a $6 million fine for the robocalls, which spoofed a local political consultant's number.New Hampshire Attorney General John M. Formella emphasized that these actions aim to deter election interference using AI. The incident has heightened concerns about AI's potential misuse in elections. FCC Chairwoman Jessica Rosenworcel proposed a rule requiring political advertisers to disclose AI use in ads, while the FCC also proposed a $2 million fine against Lingo Telecom for transmitting the calls.The AI-generated robocall, circulated just before the primary, used Biden's catchphrase and urged voters to stay home. Despite this, Democratic leaders encouraged a write-in campaign for Biden, leading to high voter turnout in his favor.Faked Biden Robocall Results in Charges for Democratic OperativeThe US Supreme Court has made it more challenging for Black and minority voters to contest the use of race in legislative redistricting, according to civil rights advocates. In a 6-3 ruling, the conservative majority determined that South Carolina voters failed to prove that race, rather than partisanship, influenced Republican legislators when drawing district lines. This decision raises the bar for proving racial gerrymandering and could impact redistricting cases nationwide, not just in South Carolina's 1st Congressional District.Leah Aden of the NAACP Legal Defense Fund expressed concern that it is becoming increasingly difficult for plaintiffs to demonstrate racial discrimination. The ruling, which precedes the upcoming November election, could affect similar challenges in states like North Carolina and Tennessee.Justice Samuel Alito, writing for the majority, emphasized a presumption that legislatures act in good faith, making it harder to prove racial intent without blatant evidence. Critics argue this standard allows legislators to use partisan motives as a defense against claims of racial gerrymandering.The decision follows the Supreme Court's 2019 ruling that federal courts cannot oversee partisan gerrymandering claims, further complicating challenges to discriminatory redistricting. Justice Elena Kagan, in her dissent, criticized the majority for favoring state arguments and making it tougher for challengers to succeed. This case underscores the evolving legal landscape surrounding voting rights and redistricting in the US.Supreme Court Conservatives Add New Minority Voter RoadblocksA Jackson Walker partner alleged that former Texas bankruptcy judge David R. Jones requested the firm to file a potentially false disclosure about his relationship with attorney Elizabeth Freeman. This disclosure came amidst ongoing litigation involving Jones, Freeman, and Jackson Walker, who are accused of concealing their relationship. The scandal follows Jones' resignation after admitting to the romance.In late 2022, Jones wanted the relationship kept secret as Jackson Walker negotiated with Freeman regarding its disclosure. Despite Freeman's earlier claims that the relationship had ended, the firm discovered in February 2022 that it was ongoing. After confronting Freeman, she admitted the relationship had been rekindled.Jackson Walker's recent filings argue they shouldn't be held liable for Jones' misconduct and urge rejection of the US Trustee's efforts to reclaim $13 million in fees. Jones allegedly provided a misleading proposed disclosure that omitted the romantic aspect of his relationship with Freeman and insisted the firm use it in future cases. Jackson Walker refused and proceeded to separate from Freeman.The firm claims it acted reasonably and didn't breach any ethical rules, pointing out that the US Trustee hasn't penalized Jones or Freeman. The Justice Department's bankruptcy monitor seeks to recover fees from cases where Jackson Walker failed to disclose the relationship. The case highlights the complex ethical and legal issues surrounding judicial conduct and professional responsibilities.Jackson Walker Says Judge Tried to Mislead Court on Romance (2)The U.S. Justice Department, along with 30 states, has filed a lawsuit against Live Nation and its Ticketmaster unit, accusing them of monopolizing concert tickets and promotions. The case, filed in Manhattan federal court, aims to break up Live Nation. Leading the legal team is Jonathan Kanter, head of the DOJ's antitrust division, with Bonny Sweeney as the lead attorney. Sweeney, a veteran antitrust litigator, previously co-headed the antitrust group at Hausfeld and has extensive experience in high-profile cases against companies like Google, Apple, and major credit card firms.Live Nation and Ticketmaster are defended by teams from Latham & Watkins and Cravath, Swaine & Moore, which have deep experience in antitrust defense. The companies deny the allegations and plan to fight the lawsuit. Latham & Watkins, which has long defended Live Nation in private consumer lawsuits and was involved in the 2010 merger approval, has Daniel Wall, a seasoned antitrust defender, as their executive vice president for corporate and regulatory affairs. Cravath's team, led by Christine Varney, former head of the DOJ's antitrust division, also represents major clients like Epic Games in similar high-stakes litigation.US legal team in Live Nation lawsuit includes veteran plaintiffs' attorney | ReutersThis week's closing theme is by Carl Philipp Emanuel Bach. This week's closing theme takes us back to the 18th century, honoring a pivotal figure in the transition from the Baroque to the Classical era: Carl Philipp Emanuel Bach. Born in 1714, C.P.E. Bach was the second surviving son of prolific composer Johann Sebastian Bach. Despite his illustrious lineage, C.P.E. Bach carved out his own distinct legacy, becoming one of the most influential composers of his time in his own right.Today, we commemorate his contributions to classical music as we mark the anniversary of his death on May 24, 1788. Known for his expressive and innovative style, C.P.E. Bach's music bridges the complexity of Baroque counterpoint with the emerging Classical clarity and form. His works had a profound impact on later composers, including Haydn, Mozart, and Beethoven.One of his most celebrated pieces is the "Solfeggietto in C minor," H. 220, Wq. 117/2. This energetic and technically demanding keyboard composition remains a favorite among pianists and continues to captivate audiences with its vibrant character and virtuosic passages. The "Solfeggietto" exemplifies C.P.E. Bach's mastery of the empfindsamer Stil, or 'sensitive style,' characterized by its emotional expressiveness and dynamic contrasts.As we listen to the "Solfeggietto," let us reflect on the enduring legacy of Carl Philipp Emanuel Bach, whose music continues to inspire and delight over two centuries after his passing. Join us in celebrating his remarkable contributions as we close this week with the lively and spirited sounds of his timeless composition.Without further ado, “Solfeggietto in C minor” by Carl Philipp Emanuel Bach, enjoy.  Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

Wharton professor Keith Weigelt and President and CEO of Castle Oak Securities L.P. David R. Jones join host Kenneth L. Shropshire, faculty director of Wharton's Coalition for Equity and Opportunity, to talk about the inequities in finance and financial wellbeing.They discuss the racial wealth gap, and the role of access, opportunity, and education. Learn about the solutions Wharton is pursuing to address these disparities, and how business leaders and financial institutions like Castle Oak can contribute to closing the wealth gap. This interview is part of a special 4-part series called “Opportunity Matters.” Hosted on Acast. See acast.com/privacy for more information.

The latest installment of the weekly review features Rite Aid's move to “self-finance” MedImpact's $575 million stalking horse bid, Reorg's analysis of challenging conditions for regional airlines, Pennsylvania Real Estate Investment Trust's looming $1 billion maturity and the latest news in the conflicts-of-interest scandal tied to former bankruptcy judge David R. Jones. As always, we also bring you a preview of what's on tap for this week. Reorg is always looking for feedback to help us improve the podcast experience. Please take a moment to complete this short survey and let us know how we're doing. https://www.research.net/r/Reorg_podcast_survey For more information on our latest events and webinars: reorg.com/resources/events-and-webinars/ Sign up to our weekly newsletter Reorg on the Record: reorg.com/resources/reorg-on-the-record/ #leveragedfinance #highyield #restructuring #performingcredit #distresseddebt #debtrestructuring #leveragedloans

Join Roger in this week's Liberty + Leadership Podcast as he speaks with Randal Teague, chairman of The Fund for American Studies. Roger and Randy talk about his career journey in law and politics, while covering history, economics, international trade, and civil society.  They discuss the need for a fresh approach to journalism and how America's polarization can be countered with courageous student leaders – both issues that TFAS strives to address. Randy and Roger also talk about the significance of teaching American history in high schools, his work with the Victims of Communism Memorial Foundation & Museum and his pride in his four children.  Randy Teague has been a member of TFAS's Board of Trustees since 1979 and was elected as chairman in 1998. Randy worked closely with one of TFAS's five founders, David R. Jones, at the time of the organization's incorporation. He served as editor of TFAS's publications in the 1970s; was a co-founder of TFAS Prague in 1993 and the founder of TFAS Greece in 1996. He also helped conceptualize the Capital Semester program in 2003.  Early in his career, Randy worked for former Rep. William C. Cramer of Florida, volunteered for the Goldwater presidential campaign, worked alongside Congressman Jack Kemp during the transformative tax reduction of the 1970s and practiced law in both Boston and Washington, D.C. Randy holds a bachelor's degree from American University, and J.D. and LL.M. with honors law degrees from George Washington University. He has also been conferred two honorary doctorates in law and humanities. The Liberty + Leadership Podcast is hosted by TFAS President Roger Ream and produced by kglobal. This episode was recorded at Reason Magazine's podcast studio. If you have a comment or question for the show, please drop us an email at podcast@TFAS.org. To support TFAS and its mission, please visit TFAS.org/support. To read a full transcript of the episode, click here.Support the show

https://www.enochiangrimoire.com20% Discount with Code: DRDYESupport this podcast at — https://redcircle.com/magick-without-fears-frater-r-c-hermetic-podcast/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Held in conjunction with Sheppard Mullin's "Restructure This!" podcast, this special ABI podcast features Bankruptcy Judges Marvin Isgur and David R. Jones of the U.S. Bankruptcy Court for the Southern District of Texas (Houston) discussing a number of important issues, such as third-party releases and venue reform, with host Justin Bernbrock, a partner at Sheppard Mullin. Click below to listen. For previous episodes of ABI's podcasts, please click here. [https://www.abi.org/newsroom/podcasts] To listen to previous episodes of Sheppard Mullin's "Restructure This!" podcast, please click here. [https://www.sheppardmullin.com/podcasts-restructure-this-podcast]

In this special installment of ‘Restructure This!' sponsored by the American Bankruptcy Institute, we welcome Chief Judge David R. Jones and Judge Marvin Isgur from the United States Bankruptcy Court for the Southern District of Texas. The two esteemed jurists collectively have several decades of experience on the bench and have presided over some of the largest chapter 11 filings in recent memory, including Seadrill, J.C. Penney, iHeartMedia, and Ultra Petroleum. As part of today's conversation, the judges opine on venue reform, third party releases, one day “prepacks,” and the propriety of repeat independent directors in chapter 11.  What We Discussed in This Episode: The importance that the judges place on consumer debtor cases  The basis for the rise of large chapter 11 filings in the Southern District of Texas  Whether the current venue statute needs reform Policy concerns regarding third-party releases The circumstances in which expedited chapter 11 cases are appropriate The current independent director framework and whether legislative reform is necessary What separates great restructuring lawyers from others   Contact Information:   Chief Judge David R. Jones  Judge Marvin Isgur

  Episode 6: David R. Jones: Adult Horror   In This Episode, You’ll Hear:  (Podcast run time 31 minutes)   1:00 - Introduction to David R. Jones; Adult Horror Author 2:07 - David talks about when he knew he was an author 3:26 - David shares his titles 5:05 - Vikki & David discuss Bigfoot, squirrels, and the PNW 6:23 - David shares about his self-publishing journey 10:17- David shares his thoughts about getting an agent 11:24 - David gives his marketing tips 13:35 - David discusses support & network groups 15:00 - David talks about his inspiration & motivation 17:23 - David reads from The Birthright of Blood     Connect with  David R. Jones:   Web address: www.davidrjonesauthor.com Email: davidrjonesauthor@gmail.com Facebook: https://www.facebook.com/davidrjonesauthor/ Twitter: https://twitter.com/DavidRJones01     Links And Resources Mentioned In This Episode:   Create Space: https://www.createspace.com   Podcast Music Credits:   Artist: Kevin MacLead Title: Backbay Lounge Album: Teh Jazzes, 2017 Website: https://incompetech.com/music/     Thanks For Listening   Thanks for listening!. If you have something you’d like to share with me, please connect with us on Facebook, Instagram, Twitter, or our website.

For our inaugural episode, we tackle the idea of universal summer jobs for all New York City youth. In February of 2016 Lazar Treschan, Director of Youth Policy at CSS, produced a report proposing the idea that all students who want one should have access to summer employment. Not only should they get a job, but that job should be connected integrated with their schooling. In this podcast, we hear from David R. Jones, the President and CEO of CSS, about our proposal and why summer jobs are so important for young people. Then we head up to the Bronx to see first-hand one school that is working hard to provide meaningful summer employment to their students; and we end up at a boat building workshop on the Bronx River.

This show is dedicated to: Pfc. David R. Jones, Jr. 21, died in a non-combat incident on October 24, 2010 in Baghdad. Military officials say he was found with a gunshot wound in his barracks in Baghdad on October 24th. His mother, Theresa Bennett, said a military official told her the death is being investigated as a possible suicide, but she thinks there is much more to the story.   Defending the Republic with Annie "The Radio Chick" and Dan, of Pundit Press Radio is an ongoing discussion of recent events, issues and the upcoming elections. Special Guest: Neil McCabe, is a senior investigative reporter and editor at HumanEvents.com, and a columnist for the Canada Free Press and Townhall.com. McCabe deployed with the Army Reserve to Iraq for 15 months as a combat historian. For many years, he was a reporter and photographer for "The Pilot," Boston's Catholic paper. He was also the editor of the free community papers "The Somerville (Mass.) News and "The Alewife (North Cambridge, Mass.)." Email him: neilwmccabe@gmail.com Follow him on Twitter: @neilwmccabe. Special Guest:  Comedian Evan Sayet  was born in NYC and went to school in Rochester, NY. He would soon move out to Hollywood in order to pursue a career as a stand-up comedian, television writer, and eventually video producer. However, post 9-11, he rethought (or more accurately, thought about for the first time) his political and social beliefs. Evan recognized that he had been acting as a knee-jerk Liberal, but was, in reality, a conservative at heart. From that moment, he has dedicated himself to conserving and promoting the values of the America that has given him freedom and allowed him to pursue his life of liberty and happiness. http://evansayet.com/evan-sayet/

This show is dedicated to: Pfc. David R. Jones, Jr. 21, died in a non-combat incident on October 24, 2010 in Baghdad. Military officials say he was found with a gunshot wound in his barracks in Baghdad on October 24th. His mother, Theresa Bennett, said a military official told her the death is being investigated as a possible suicide, but she thinks there is much more to the story.  Defending the Republic with Annie "The Radio Chick" and Dan, of Pundit Press Radio is an ongoing discussion of recent events, issues and the upcoming elections.Special Guest: Neil McCabe, is a senior investigative reporter and editor at HumanEvents.com, and a columnist for the Canada Free Press and Townhall.com. McCabe deployed with the Army Reserve to Iraq for 15 months as a combat historian. For many years, he was a reporter and photographer for "The Pilot," Boston's Catholic paper. He was also the editor of the free community papers "The Somerville (Mass.) News and "The Alewife (North Cambridge, Mass.)." Email him: neilwmccabe@gmail.com Follow him on Twitter: @neilwmccabe.Special Guest:  Comedian Evan Sayet  was born in NYC and went to school in Rochester, NY. He would soon move out to Hollywood in order to pursue a career as a stand-up comedian, television writer, and eventually video producer. However, post 9-11, he rethought (or more accurately, thought about for the first time) his political and social beliefs. Evan recognized that he had been acting as a knee-jerk Liberal, but was, in reality, a conservative at heart. From that moment, he has dedicated himself to conserving and promoting the values of the America that has given him freedom and allowed him to pursue his life of liberty and happiness. http://evansayet.com/evan-sayet/

This show is dedicated to: Pfc. David R. Jones, Jr. 21, died in a non-combat incident on October 24, 2010 in Baghdad. Military officials say he was found with a gunshot wound in his barracks in Baghdad on October 24th. His mother, Theresa Bennett, said a military official told her the death is being investigated as a possible suicide, but she thinks there is much more to the story.  Defending the Republic with Annie "The Radio Chick" and Dan, of Pundit Press Radio is an ongoing discussion of recent events, issues and the upcoming elections.Special Guest: Neil McCabe, is a senior investigative reporter and editor at HumanEvents.com, and a columnist for the Canada Free Press and Townhall.com. McCabe deployed with the Army Reserve to Iraq for 15 months as a combat historian. For many years, he was a reporter and photographer for "The Pilot," Boston's Catholic paper. He was also the editor of the free community papers "The Somerville (Mass.) News and "The Alewife (North Cambridge, Mass.)." Email him: neilwmccabe@gmail.com Follow him on Twitter: @neilwmccabe.Special Guest:  Comedian Evan Sayet  was born in NYC and went to school in Rochester, NY. He would soon move out to Hollywood in order to pursue a career as a stand-up comedian, television writer, and eventually video producer. However, post 9-11, he rethought (or more accurately, thought about for the first time) his political and social beliefs. Evan recognized that he had been acting as a knee-jerk Liberal, but was, in reality, a conservative at heart. From that moment, he has dedicated himself to conserving and promoting the values of the America that has given him freedom and allowed him to pursue his life of liberty and happiness. http://evansayet.com/evan-sayet/

This show is dedicated to: Pfc. David R. Jones, Jr. 21, died in a non-combat incident on October 24, 2010 in Baghdad. Military officials say he was found with a gunshot wound in his barracks in Baghdad on October 24th. His mother, Theresa Bennett, said a military official told her the death is being investigated as a possible suicide, but she thinks there is much more to the story.  Defending the Republic with Annie "The Radio Chick" and Dan, of Pundit Press Radio is an ongoing discussion of recent events, issues and the upcoming elections.Special Guest: Neil McCabe, is a senior investigative reporter and editor at HumanEvents.com, and a columnist for the Canada Free Press and Townhall.com. McCabe deployed with the Army Reserve to Iraq for 15 months as a combat historian. For many years, he was a reporter and photographer for "The Pilot," Boston's Catholic paper. He was also the editor of the free community papers "The Somerville (Mass.) News and "The Alewife (North Cambridge, Mass.)." Email him: neilwmccabe@gmail.com Follow him on Twitter: @neilwmccabe.Special Guest:  Comedian Evan Sayet  was born in NYC and went to school in Rochester, NY. He would soon move out to Hollywood in order to pursue a career as a stand-up comedian, television writer, and eventually video producer. However, post 9-11, he rethought (or more accurately, thought about for the first time) his political and social beliefs. Evan recognized that he had been acting as a knee-jerk Liberal, but was, in reality, a conservative at heart. From that moment, he has dedicated himself to conserving and promoting the values of the America that has given him freedom and allowed him to pursue his life of liberty and happiness. http://evansayet.com/evan-sayet/

Joining Doug to talk about poverty, the poor, politics, and public policy is David R. Jones, President and Chief Executive Officer of the Community Service Society of New York.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon's role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.